Cascadian Therapeutics Inc. plans to offer and sell common stock and series E convertible preferred stock in concurrent but separate underwritten public offerings.

The company expects to grant underwriters an option to buy additional common shares.

The series E convertible preferred stocks offered are nonvoting and convertible into common shares. The conversion will be prohibited if it will result in the ownership of more than 19.99% of the company's outstanding common stock by the holder and its affiliates.

Net proceeds of the offerings will be used to fund the tucatinib HER2CLIMB trial, to support its development in other indications through company- or investigator-sponsored trials, as well as for working capital and other general corporate purposes.

Cowen and Co. LLC and Barclays Capital Inc. are acting as joint book-running managers. Raymond James & Associates Inc. is acting as the lead manager, with BTIG LLC acting as a co-manager in the offerings.